Evidence map›Paper›PMID 38188297›Full record

ArticleFrontiers in oncology2023

MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results.

Felipe F Souza, Gina D'Amato, Emily Elizabeth Jonczak, Philippos Costa, Jonathan C Trent, Andrew E Rosenberg, Raphael Yechieli, H Thomas Temple, Pradip Pattany, Ty K Subhawong

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Felipe F SouzaDepartment of Radiology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Gina D'AmatoSylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, United States.
Emily Elizabeth JonczakSylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, United States.
Philippos CostaDepartment of Internal Medicine, Yale Medicine, New Haven, CT, United States.
Jonathan C TrentSylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, United States.
Andrew E RosenbergSylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, United States.
Raphael YechieliSylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, United States.
H Thomas TempleSylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, United States.
Pradip PattanyDepartment of Radiology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
Ty K SubhawongDepartment of Radiology, Leonard M. Miller School of Medicine, University of Miami, Miami, FL, United States.
University of Miami · USSylvester Comprehensive Cancer Center · USUniversity of Miami Health System · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Because size-based imaging criteria poorly capture biologic response in desmoid-type fibromatosis (DF), changes in MRI T2 signal intensity are frequently used as a response surrogate, but remain qualitative. We hypothesized that absolute quantification of DF T2 relaxation time derived from parametric T2 maps would be a feasible and effective imaging biomarker of disease activity. Methods: This IRB-approved retrospective study included 11 patients with DF, managed by observation or systemic therapy, assessed by 3T MRI. Tumor maximum diameter, volume, and T2-weighted signal intensity were derived from manual tumor segmentations. Tumor:muscle T2 signal ratios were recorded. Two readers measured tumor T2 relaxation times using a commercial T2 scanning sequence, manual ROI delineation and commercial calculation software enabling estimation of reader reliability. Objective response rates based on RECIST1.1 and best responses were compared between size-based and signal-based parameters. Results: Median patient age was 52.6 years; 8 subjects were female (73%). Nine patients with longitudinal assessments were followed for an average of 314 days. Median baseline tumor diameter was 7.2 cm (range 4.4 - 18.2 cm). Median baseline T2 was 65.1 ms (range 40.4 - 94.8 ms, n=11); median at last follow-up was 44.3 ms (-32% from baseline; range 29.3 - 94.7 ms, n=9). T2 relaxation times correlated with tumor:muscle T2 signal ratios, Spearman p=0.78 (p<0.001). T2 mapping showed high inter-reader reliability, ICC=0.84. The best response as a percentage change in T2 values was statistically significant (mean -17.9%, p=0.05, paired t-test) while change in diameter was not (mean -8.9%, p=0.12). Conclusions: Analysis of T2 relaxation time maps of DF may offer a feasible quantitative biomarker for assessing the extent of response to treatment. This approach may have high inter-reader reliability.

Indexed as

aggressive fibromatosisdesmoid-type fibromatosismagnetic resonance imagingmultiparametric magnetic resonance imagingneoplasmssoft tissue tumortherapy response

Identifiers

PMID38188297
PMCPMC10766853
OpenAlexW4390111314

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.